BioNTech und DualityBio erhalten Breakthrough-Therapy-Status der FDA für ADC-Kandidaten BNT323/DB-1303 zur Behandlung von Gebärmutterkrebs
December 21, 2023 08:00 ET
|
BioNTech SE
Breakthrough-Therapy-Status basiert auf Phase-1/2-Daten zur Sicherheit und Wirksamkeit in Patientinnen mit Human Epidermal Growth Factor Receptor 2 („HER2“) -exprimierendem, fortgeschrittenen...
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
December 21, 2023 08:00 ET
|
BioNTech SE
Designation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced endometrial cancer with encouraging early signs of...
Elucida Oncology Presents Encouraging Clinical Data from Phase 1/2 Study of ELU001 in Solid Tumors Overexpressing Folate Receptor Alpha at ESMO Congress 2023
October 23, 2023 08:00 ET
|
Elucida Oncology, Inc
Anti-tumor activity observed across all levels of folate receptor alpha (“FRα”) expression89% of patients with cancers expressing FRα showed stable disease or a partial response following treatment...
Elucida Oncology Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
September 11, 2023 10:00 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today an...
Elucida Oncology Appoints Ramzi Benamar as Chief Financial Officer
August 24, 2023 11:00 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that...
Elucida Oncology Announces First Patient Dosed with ELU001 in Expansion Cohort of its Phase 1/2 Clinical Trial
July 20, 2023 11:45 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that the...
Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023 16:18 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer
May 12, 2023 08:00 ET
|
Onconova Therapeutics, Inc.
Showcase to feature presentations by key opinion leaders Drs. Gaël Roué and Bhavana Pothuri Showcase to take place on May 18, 2023 at 11:00 a.m. ET NEWTOWN, Pa., May 12, 2023 (GLOBE NEWSWIRE) --...
Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer
May 11, 2023 08:00 ET
|
Onconova Therapeutics, Inc.
Prior data provide clinical proof-of-concept for narazaciclib’s mechanism of action in endometrial cancer Preliminary data from trial’s Phase 1 portion expected in 4Q 2023 NEWTOWN, Pa., May 11,...
Endometrial Cancer Market Growing Significantly | AstraZeneca, Karyopharm, Evergreen therapeutics, ImmunoGen, Inc., Merck, Tesaro, Inc., Abbott, Roche, Chimerix, Bayer, ImmunoGen, Inc., Incyte, Eli Lilly, Gilead, Genentech Expected to Boost
April 03, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 03, 2023 (GLOBE NEWSWIRE) -- Endometrial Cancer Market Growing Significantly | AstraZeneca, Karyopharm, Evergreen therapeutics, ImmunoGen, Inc., Merck, Tesaro, Inc., Abbott,...